GDANSK (Reuters) -The Polish arm of Spanish lender Santander could pay dividends reaching 100% of annual profits ... found themselves unable to get approval from the regulator for full dividend ...

Buy now, pay later apps (BNPL) offer point-of-sale loans ... Consider whether the BNPL app runs a hard or soft credit inquiry to determine approval. A soft credit inquiry won’t harm your credit ...

and invest in sustainable recycling technologies that can help drive a future where 100% of tires are recycled and reclaimed into sustainable, circular end-use markets.” Building on the 2021 Rubber ...

And does strong price action mean now is a good time to buy ... approved, or endorsed by included advertisers. Motley Fool Money does not cover all offers on the market. Motley Fool Money is 100% ...

Additionally, you can buy it from websites like as financial institutions, brokerage firms, and mobile e-wallets. The market price of actual gold determines the return on this investment, whereas ...

But news emerged that he used the funds to pay his former partner. Yesterday, news broke that White and Linda Rogan had settled their matters outside of court. But fresh news today could be ...

However, if you go for something in 100% wool with a bit of weight, you’ll be staying cosy – trust us. What is the cheapest winter coat you can buy ... launched its now iconic in-built ...

Waaree Energies IPO subscription status: The initial public offering (IPO) of Waaree Energies continues to garner a favorable response from investors on the second day of its opening. Waaree Energies’ ...

Over half of buy now, pay later ... reviewed, approved, or endorsed by included advertisers. Motley Fool Money does not cover all offers on the market. Motley Fool Money is 100% owned and operated ...

On Thursday, Guggenheim reaffirmed its Buy rating on Acadia Pharmaceuticals (NASDAQ:ACAD) stock, following the company's announcement that Daybue (trofinetide) has received approval for the treatment ...

On Tuesday, H.C. Wainwright upgraded shares of NovoCure Ltd. (NASDAQ: NASDAQ:NVCR) from Neutral to Buy, setting a price target of $30.00. The upgrade followed the recent FDA approval of NovoCure's ...

(NASDAQ: NASDAQ:NVCR) from Neutral to Buy, setting a price target of $30.00. The upgrade followed the recent FDA approval of NovoCure's Optune Lua for the treatment of metastatic non-small cell ...